Lonza Group Ag (OTCMKTS:LZAGY) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company’s Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. “
Separately, Jefferies Group LLC raised Lonza Group Ag from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th.
Shares of Lonza Group Ag (OTCMKTS:LZAGY) opened at 26.63 on Wednesday. The stock has a 50 day moving average price of $24.67 and a 200 day moving average price of $21.54. Lonza Group Ag has a 52-week low of $15.27 and a 52-week high of $26.63. The company has a market capitalization of $16.33 billion, a PE ratio of 42.74 and a beta of 1.04.
About Lonza Group Ag
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients for life-saving medicines; manufactures commercial bulk drug substance of monoclonal antibodies and recombinant proteins from mammalian cell cultures; and chemical contract manufacturing services, such as microbials, peptides, and small molecules.
Receive News & Ratings for Lonza Group Ag Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group Ag and related companies with MarketBeat.com's FREE daily email newsletter.